This phase 2 trial aimed to evaluate the efficacy and safety of chidamide, an orally active HDAC inhibitor, plus the R‐GemOx regimen for relapsed/refractory (R/R) DLBCL. The gene discussed is HDAC9; the disease is diffuse large B-cell lymphoma.